BioInvent International AB (STU:BIX) ROCE % : -52.48% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is BioInvent International AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioInvent International AB's annualized ROCE % for the quarter that ended in Dec. 2024 was -52.48%.

BioInvent International AB ROCE % Historical Data

The historical data trend for BioInvent International AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB ROCE % Chart

BioInvent International AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-16.47

-25.92

-2.69

-24.85

-41.76

BioInvent International AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-33.28	-27.77	-50.49	-40.33	-52.48

BioInvent International AB ROCE % Calculation

BioInvent International AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-40.952	/	( ( (125.172 - 6.787)	+	(86.001 - 8.277) )	/ 2 )
	=	-40.952	/	( (118.385	+	77.724)	/ 2 )
	=	-40.952	/	98.0545
	=	-41.76 %

BioInvent International AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-43.772	/	( ( (95.788 - 6.7)	+	(86.001 - 8.277) )	/ 2 )
	=	-43.772	/	( ( 89.088	+	77.724 )	/ 2 )
	=	-43.772	/	83.406
	=	-52.48 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

BioInvent International AB (STU:BIX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioInvent International AB ROCE % Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (STU:BIX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BINV:Sweden 0H22:UK

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines